Roche shares: Goals not achieved in important Alzheimer’s study – Morphosys also reports failure with gantenerumab

His Alzheimer’s program with the candidate gantenerumab has failed to meet its goals.

For example, treatment with gantenerumab in the affected patients did not slow down the disease. The degree of beta-amyloid removal, the deposits in the brain typical of Alzheimer’s, was also lower than expected.

Nevertheless, Roche will continue to fight against Alzheimer’s, “one of the most complex neurological diseases and a major public health challenge,” as the statement said. Roche will continue to develop and provide tests for early and accurate Alzheimer’s diagnosis and has a pipeline of investigational drugs for different targets, types and stages of the disease.

hopes dashed

The news is likely to be received with disappointment at first. Because even if analysts had repeatedly emphasized that they considered the chances of success of this study to be very low, some hope had recently spread on the market. The reason for this was the competitors Biogen/Eisai, who had recently achieved positive results and thus a breakthrough in a study with a similar approach.

A few numbers show how rocky Alzheimer’s research has been so far. According to CS analyst Lorenzo Biasio, since 1995 more than $42.5 billion in private spending has gone into research and development projects for Alzheimer’s involving nearly 185,000 patients. Under normal circumstances, that would have been enough to develop about two dozen drugs, the analyst said.

The pharmaceutical industry is under great pressure when it comes to Alzheimer’s. According to calculations by the Alzheimer’s Disease International organization, 139 million people worldwide could develop Alzheimer’s by 2050. Already today, about 55 million are affected by this devastating disease. In addition, the global cost of illness could double to around two trillion US dollars by 2030.

Morphosys also reports failure with gantenerumab in Alzheimer’s study

The biotech group Morphosys has suffered a failure in the treatment of Alzheimer’s with its monoclonal antibody gantenerumab. Two clinical studies investigating gantenerumab in early Alzheimer’s disease (AD) did not meet their primary endpoint of slowing the clinical progression of the disease, according to license partner Roche.

In the Phase 3 Graduate 1 and 2 studies, the breakdown of beta-amyloid, the protein that builds up in plaques in the brains of people with Alzheimer’s disease, was reported to be less than expected. Gantenerumab was well tolerated, including when administered subcutaneously.

The graduate program evaluated gantenerumab in people with mild cognitive impairment (MCI) due to Alzheimer’s disease or mild Alzheimer’s dementia over a 27-month period.

The antibody will be clinically developed under license by the Swiss pharmaceutical giant Roche and will also be marketed after a possible later approval. Morphosys would then be entitled to performance-based milestone payments and tiered royalties of between 5.5 and 7.0 percent of potential gantenerumab net sales. However, 60 percent of the royalties would go to Royalty Pharma, which made billions available to Morphosys last year after a financial agreement so that the biotech– Can develop into a biopharmaceutical company.

BASEL (awp) / FRANKFURT (Dow Jones)

Leave a Comment